Our lab is part of the Department of Pharmacology and Cancer Biology at Duke University. We are also members of the Duke Cancer Institute and the Duke Molecular Physiology Institute. We have a longstanding interest in understanding the structure and function of metabolic networks in health and pathology. We are a diverse group with equally diverse skills in analytical chemistry, genetics, computational biology, bioinformatics, and mathematics, and biochemistry allowing us to solve complex biological problems with an integrative and collaborative approach.
Our research focuses on an integrated understanding of metabolism in health and disease. We direct these efforts toward understanding the role of altered metabolism in cancer, emphasizing its targetable liabilities and downstream effects on cellular physiology, notably its influence on the chromatin state. At the core of this effort lies the utilization of computational modeling and high throughput technologies such as mass spectrometry-based metabolomics. We define our systems biology approach through combining these tools with an integration of genetics, biochemistry, and cell biology. Investing such effort we believe has the potential to fundamentally alter our understanding of disease biology and lead to innovative therapies.
SPHK1 is a novel target of metformin in ovarian cancer.
IDH3α regulates one-carbon metabolism in glioblastoma.
Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.
Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells.
Serine synthesis through PHGDH coordinates nucleotide levels by maintaining central carbon metabolism.